Nombramiento de Sath Nirmalananthan para la Junta
14 de marzo de 2024
Scancell Holdings plc
("Scancell" o la "Compañía")
Appointment of Sath Nirmalananthan to the Board of Directors
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that Sath Nirmalananthan, Chief Financial Officer, has been appointed to the Company's Board of Directors (the "Board") with immediate effect.
Sath was appointed as the Company's Chief Financial Officer on 29 August 2023, having previously served as Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. He brings more than 15 years' experience in the healthcare sector, and has held roles at FTSE and NASDAQ listed companies, including Reckitt and BTG. Prior to this Sath held positions in investment banking at Nomura, and at KPMG. Sath is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales (ICAEW), and sits as a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR). He was awarded a BSc in Pharmacology from King's College, London.
Dr Jean-Michel Cosséry, Non-Executive Chairman of Scancell, comentado: "Since joining Scancell in August last year, Sath has brought considerable experience and expertise to the role, overseeing our successful £12 million fundraise from new and existing investors. Our focus remains on progressing SCIB1 and Modi-1 through the clinic whilst also actively seeking out-licensing, collaborations, and partnerships to accelerate the development and commercialisation of our products and platforms. Working closely with the Board, and Executive team, Sath will be instrumental in driving us towards realising the potential of these treatments for patients, while creating and delivering significant long-term value for our shareholders."
Commenting on his new appointment, Sath Nirmalananthan, Chief Financial Officer and Director of Scancell, said: "I am proud to take on this expanded role as a member of the Board, and I look forward to working with my fellow Board members and the wider team to deliver our goals for 2024 and beyond. This is an exciting time to be part of Scancell, as we continue to build significant momentum and approach a number of important clinical milestones, anticipated later this year, including further data from both the SCOPE and ModiFY trials."
Información adicional
In accordance with the AIM Rules, the following information required to be disclosed in relation to Sath Nirmalananthan is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.
Nombre completo y edad: Sathijeevan Nirmalananthan, aged 38
| |
Directores actuales | Directorios anteriores (últimos 5 años) |
PNSN Company Limited | Oxsed Limited |
DNA Fit Limited | |
DNA Sport Limited | |
DNAFIT Life Sciences Limited | |
Prenetics EMEA Limited | |
Prenetics Consumer Healthcare Limited | |
Duo Doc Limited | |
Norse Medica Limited | |
SP Care Holdings Limited |
Mr Sath Nirmalananthan does not have an interest in any ordinary shares or share options in Scancell.
Para más información, por favor póngase en contacto con: | |
Scancell Holdings plc | +44 0 20 3709 5700 |
Dr. Jean-Michel Cosséry, presidente no ejecutivo | |
Profesora Lindy Durrant, directora ejecutiva | |
Stifel Nicolaus Europa limitada (Asesor designado y conjunto Broker) | +44 0 20 7710 7600 |
Nicholas Moore / Samira Essebiyea (Banca de inversión en atención médica) | |
Nick Adams/Nick Harland (corretaje corporativo)
| |
WG Partners LLP (Conjunto Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby
| +44 0 20 3705 9330
|
Panmure Gordon (Reino Unido) Limited (Articulación Broker) | +44 0 20 7886 2500 |
Freddy Crossley / Emma Earl (Finanzas corporativas) | |
Rupert Dearden (Corretaje corporativo) | |
Consejo ICR | +44 0 20 3709 5700 |
Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
Sobre Scancell
Scancell es una compañía biofarmacéutica en etapa clínica que está aprovechando su investigación patentada, desarrollada durante muchos años de estudio del sistema inmunitario adaptativo humano, para generar medicamentos novedosos para tratar necesidades importantes no satisfechas en cáncer y enfermedades infecciosas. La Compañía está construyendo una cartera de productos innovadores utilizando sus cuatro plataformas tecnológicas: Moditope® e ImmunoBody® para vacunas y GlyMab® y AvidiMab® para anticuerpos.
Las respuestas inmunitarias adaptativas incluyen anticuerpos y células T (CD4 y CD8), que pueden reconocer células dañadas o infectadas. Para destruir dichas células cancerosas o infectadas, Scancell utiliza vacunas para inducir respuestas inmunitarias o anticuerpos monoclonales (mAb) para redirigir las células inmunitarias o los fármacos. El enfoque único de la Compañía es que sus productos innovadores apuntan a modificaciones de proteínas y lípidos. Para las vacunas (Moditope® e ImmunoBody®) esto incluye la citrulinación y la homocitrulación de proteínas, mientras que su cartera de mAb se dirige a los glicanos o azúcares que se agregan a las proteínas y/o lípidos (GlyMab®) o mejora la potencia de los anticuerpos y su capacidad para destruir directamente las células tumorales (AvidiMab®).
Para obtener más información sobre Scancell, visite: https://www.scancell.co.uk/
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.